Our study observed that the rates of grade ≥ 3 hematologic toxicities, including anemia, neutropenia, and thrombocytopenia, did not increase in patients receiving CDK4/6 inhibitors who also underwent palliative radiotherapy compared to those who did not receive radiotherapy. The gene discussed is CDK4; the disease is anemia (phenotype).